Physician profile
Myat San
NPI 1134284581
$9,224.91
in general payments reported to CMS, 2019-2025
35 companies · $763 in 2025
The $763 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $1,181 · 2021: $2,126 · 2022: $2,541 · 2023: $889 · 2024: $229 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,299.99 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $897.50 | 2021-2025 | Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $893.85 | 2019-2023 | Trulance |
| Glaxosmithkline, LLC. | $859.84 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.43 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $604.72 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $389.46 | 2019-2022 | |
| Amgen INC. | $384.93 | 2019-2023 | Repatha, Otezla |
| Abbott Laboratories | $362.71 | 2021-2023 | Freestyle Libre 2 |
| Novo Nordisk INC | $344.68 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $328.73 | 2019-2023 | Verquvo, Janumet |
| Medtronic, INC. | $310.77 | 2022-2025 | Linq II, Closurefast |
| Allergan, INC. | $266.46 | 2019-2020 | |
| Viiv Healthcare Company | $247.41 | 2022 | |
| Astellas Pharma US INC | $213.09 | 2019-2023 | Myrbetriq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $200.79 | 2019-2022 | |
| Pfizer INC. | $182.60 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $119.90 | 2020-2025 | Livalo, Zoryve |
| Esperion Therapeutics, INC. | $96.10 | 2020-2021 | |
| Averitas Pharma INC. | $86.93 | 2023 | Qutenza |
| Horizon Therapeutics Plc | $71.59 | 2021 | |
| Ardelyx, INC. | $66.08 | 2023 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.03 | 2020-2022 | |
| Exact Sciences Corporation | $59.66 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $48.24 | 2022 | |
| Dynavax Technologies Corporation | $38.78 | 2020-2021 | |
| Emd Serono, INC. | $32.61 | 2021 | |
| Ironwood Pharmaceuticals, INC | $32.58 | 2021-2022 | |
| Renalytix Ai, INC. | $19.60 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Redhill Biopharma INC. | $19.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.90 | 2023 | Quviviq |
| Biogen, INC. | $14.84 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $14.19 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.59 | 2022 | |
| Lupin INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myat San listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.